Abstract
DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have